Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. | Eli Lilly—which has already staged multiple efforts in ...

It’s out with the old, in with the new at the FDA as the agency is unveiling a new adverse events monitoring system that joins several reporting systems into one unified platform, an effort that’s | ...

Lilly’s Japan outlay comes on the heels of a major $3 billion investment in the company’s manufacturing operations in China, where the pharma giant has pledged to set up local production for oral ...

According to a new team-up between Eisai and Pokémon, when it comes to healthy sleep habits, people of all ages have gotta catch ’em all. Eisai is partnering up with the media franchise’s “Pokémon ...

Twelve months ago, drugmakers came roaring into 2025, fueled by a massive year of growth that peaked in the fourth quarter of ...

Yet, despite the “stormy waters,” global sales of orphan drugs are projected to exceed $400 billion by 2032, according to a new report by Evaluate.

As AstraZeneca kicks off the third year of its hockey-themed “Get Body Checked Against Cancer” campaign, the pharma has tapped two celebs known for their work both on and off the ice. | As AstraZeneca ...

After strutting its stuff against blockbusters in three head-to-head psoriasis trials, UCB’s Bimzelx has conquered another powerhouse product—AbbVie’s Skyrizi—in psoriatic arthritis (PsA). | After ...

Veeva Systems, which offers life sciences companies cloud-based commercial management software and business consulting services, is venturing into the consumer-facing side of things with the ...

Skyhawk Therapeutics has named Aaron Deves as chief commercial officer, securing the expertise of an executive who oversaw ...

Eli Lilly is infusing $3 billion into its manufacturing operations in China, pledging to set up local production and supply for oral solid drugs as it works on building out capacity for its experim | ...

About five months after U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. | About five months after U.S. Health Secretary Robert F. Kennedy Jr. touted leucovorin as “an ...